Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACP 319

Drug Profile

ACP 319

Alternative Names: ACP319

Latest Information Update: 30 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acerta Pharma
  • Class Antineoplastics
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II B-cell lymphoma
  • No development reported Chronic lymphocytic leukaemia

Most Recent Events

  • 28 Mar 2019 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy, Second-line therapy or greater) in USA (PO)
  • 01 Jun 2018 Efficacy, adverse events and pharmacokinetics data from a phase I/II trial in B-cell lymphoma presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 31 Mar 2017 ACP 319 is still in phase I trials for Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top